User:Mr. Ibrahem/Enasidenib

Enasidenib, sold under the brand name Idhifa, is a medication used to treat acute myeloid leukemia (AML) with mutations of the isocitrate dehydrogenase 2 (IDH2) gene. It is used when other treatments have failed. It is taken by mouth.

Common side effects include nausea, diarrhea, high bilirubin, and lose of appetite. Other side effects may include differentiation syndrome, tumor lysis syndrome, lung problems, infertility, and kidney problems. Use during pregnancy may harm the baby. It works by blocking the action of mutated IDH2.

Enasidenib was approved for medical use in the United States in 2017. It was denied approval in Europe in 2019 due to insufficient evidence of benefit. In the United States a month of treatment costs about 29,500 USD as of 2021.